An interventional study of SIMBA Capsule in Multiple Sclerosis, sponsored by Nimble Science Ltd.. Terminated at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Nimble Science Ltd. · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.
Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 167th largest by enrollment of the 215 interventional ones that give a count, is one of 8 that started in 2023, is one of 53 with no phase, and was the 233rd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:
Kite, A Gilead Company · Sites in Canada, United States, Australia
Ages 18–75
University Health Network, Toronto · Sites in Canada
Ages 18–65
AstraZeneca · Sites in Canada, United States, Australia and 2 more countries
Ages 18–60
University of Calgary · Sites in Canada
Ages 26–59
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
257 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 60 · Phase 3 85 · Phase 4 13
First in 2001; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 177 across the 215 interventional studies, 172 across the 42 observational. Of the 200 that completed or were terminated, 97 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 257 have an industry lead sponsor. The 10 most frequent:
Nimble Science Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Nimble Science Ltd. has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
12 of the studies in Multiple Sclerosis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT06415552Robert SimpsonImplementation of Online Mindfulness-Based Stress Reduction Tailored for People with Multiple Sclerosis | 2026-12-31 |
| NCT04121468The Hospital for Sick ChildrenA Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis | 2027-03 |
| NCT05090371Novartis PharmaceuticalsA Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | 2027-04-13 |
| NCT06782490CelgeneA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | 2027-05-26 |
Add all 12 to your calendar (.ics) → With an account.
Among the 257 studies in Multiple Sclerosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.
Participants will be swallowing the SIMBA capsule which allows for minimally-invasive sampling of the microbiome and metabolome deep in the small intestine. Researchers will use the capsule samples to access the small intestinal microbiome and find abnormal metabolomic signatures in luminal fluid samples from the small bowel in Multiple Sclerosis (MS) patients compared to healthy control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant swallows and retrieves capsule in stool. Intestinal fluid samples collected by SIMBA capsules from the MS and HC participants, along with a fecal and blood samples, will be used for gut microbiome, viral and metabolomic analysis.
Device: SIMBA Capsule
Participants will swallow capsule
16s microbiome sequencing and LC-MS metabolomic analysis will be performed on these samples to compare gut microbiome and metabolite profiles of healthy control and diagnosed MS patients
Comparison of luminal fluid samples from the small bowel of MS and healthy control participants will allow us to find abnormal metabolomic signatures which can be used as biomarkers for MS.
Time frame: baseline
Comparison of blood samples from Multiple Sclerosis (MS) and healthy control participants for biomarkers of inflammation, as analysed using ELISA, protenomic methods, and commercially available assays.
Comparison of blood samples from Multiple Sclerosis (MS) and healthy control participants will aid in quantification of markers of inflammation and markers of intestinal function.
Time frame: baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Apr 2024, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nimble Science Ltd.